Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)

NCT00185185 is registered in ClinicalTrials.gov with Sankyo Pharma Gmbh as lead sponsor.

NCT NCT00185185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00185185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
Lead sponsor
Sankyo Pharma Gmbh
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2001
Completion date
February 28, 2006
Enrollment
165 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease, essential hypertension